Pharmaceutical

Cadonilimab by Akeso for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).

Dec 22, 2023 - 18:00
Cadonilimab is under clinical development by Akeso and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).
Read the original article

Tags:

Previous Article

MRNA-2752 by Moderna for Transitional Cell Cancer (Urothelial Cell Cancer): Like...

Next Article

SOR-007 by Nanology for Metastatic Adenocarcinoma of The Pancreas: Likelihood of...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Regeneron’s bispecific lymphoma antibody odronextamab wins FDA priority review

Regeneron’s bispecific lymphoma antibody odronextamab w...

Sep 29, 2023

Opinion: Sobering centers offer a safe place to recover from intoxication. Every community should have one

Opinion: Sobering centers offer a safe place to recover...

Dec 13, 2023

Optimisation in operations: from theory to practice

Optimisation in operations: from theory to practice

May 5, 2024